COSENTYX  SOLUTION FOR INJECTION Izraēla - angļu - Ministry of Health

cosentyx solution for injection

novartis israel ltd - secukinumab - solution for injection - secukinumab 150 mg/ml - secukinumab - - plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy. - paediatric plaque psoriasis: cosentyx is indicated for the treatment of moderate to severe plaque psoriasis in children and adolescents from the age of 6 years who are candidates for systemic therapy. - psoriatic arthritis: cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active psoriatic arthritis in adult patients when the response to previous disease modifying anti rheumatic drug (dmard) therapy has been inadequate. - axial spondyloarthritis (axspa) : •ankylosing spondylitis (as, radiographic axial spondyloarthritis) cosentyx is indicated for the treatment of active ankylosing spondylitis in adults who have responded inadequately to conventional therapy. •non-radiographic axial spondyloarthritis (nr-axspa) cosentyx is indicated for the treatment of active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated c-reactive protein (crp) and/or magnetic resonance imaging (mri) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs (nsaids). - juvenile idiopathic arthritis (jia) •enthesitis-related arthritis (era) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active enthesitisrelated arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy. •juvenile psoriatic arthritis (jpsa) cosentyx, alone or in combination with methotrexate (mtx), is indicated for the treatment of active juvenile psoriatic arthritis in patients 6 years and older whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.hidradenitis suppurativa (hs)cosentyx is indicated for the treatment of active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic hs therapy

Densitin   capsule    Ēģipte - angļu - EDA (Egyptian Drug Authority)

densitin capsule

شركة فارماكير ايجيبت للتوكيلات التجارية بتصريح من أر اكس فيتامينس - انك، أمريكا -

Lamictal Liquitab 100 mg Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

lamictal liquitab 100 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - lamotrigine 100 mg - 100 mg

Lamictal Liquitab 25 mg Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

lamictal liquitab 25 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - lamotrigine 25 mg - 25 mg

Lamictal Liquitab 5 mg Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

lamictal liquitab 5 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - lamotrigine 5 mg - 5 mg

Seroxat Tab 20 mg Jordānija - angļu - JFDA (Jordan Food & Drug Administration - المؤسسة العامة للغذاء والدواء)

seroxat tab 20 mg

مستودع أدوية سليمان طنوس وأولاده - suleiman tannous & sons co. ltd - paroxetine 20 mg - 20 mg